Formulation: A solid
Formal Name: (1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino]-5-(propyl-1,1,2,2,3,3,3-d7-thio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-1,2-cyclopentanediol
Purity: ≥99% deuterated forms (d1-d7)
Formula Markup: C23H21D7F2N6O4S
Formula Weight: 529,6
Shelf life (days): 1460
CAS Number: 1265911-55-4
Notes: Ticagrelor-d7 is intended for use as an internal standard for the quantification of ticagrelor (Item No. 15425) by GC- or LC-MS. Ticagrelor is a reversible antagonist of the platelet purinergic P2Y12 receptor (Ki = 14 nM; IC50 = 1.8 μM), which is the main receptor responsible for ADP-induced platelet aggregation.{25099,23701} It functions by directly changing the conformation of the P2Y12 receptor to inhibit ADP binding.{23699} Formulations containing ticagrelor have been used to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome.